Clinical trial
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or…
NCT00003230 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003230 |
|---|---|
| Title | Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia |
| Official title | Paclitaxol (Taxol) for Refractory or Relapsed Acute Leukemia in Elderly Patients, and Blast Crisis of Chronic Myelogenous Leukemia: A Multicenter Phase I/II Study |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | paclitaxel |
| Enrollment | 33 |
| Start date | Jan 1, 1998 |
| Primary completion | Jul 1, 2000 |
| Completion | Jul 1, 2000 |
| First posted | Jul 8, 2004 |
| Last update posted | May 15, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: